Molecular Mechanisms and Therapeutic Advances in Sickle Cell Disease: Insights into Genetics, Pathophysiology, and Treatment Strategies

Chinedu-madu Jane Ugochi

Faculty of medical laboratory science, Federal university Otuoke, Bayelsa State, Nigeria

Abstract

Red blood cells (RBCs) with aberrant haemoglobin S (HbS) are indicative of sickle cell disease (SCD), a severe hereditary hemoglobinopathy. The characteristics of haemoglobin are changed by a single point mutation in the β-globin gene, which causes a valine to replace glutamic acid at position six. RBCs sickle as a result of HbS molecules polymerising in a deoxygenated environment. Numerous pathophysiological processes, such as haemolysis, vaso-occlusion, inflammation, oxidative stress, endothelial dysfunction, and multi-organ damage, are facilitated by these malformed cells. The molecular causes of sickle cell disease (SCD) are examined in this review, ranging from genetic mutations and aberrant protein interactions to cellular reactions and systemic effects. The dynamics of polymerisation, aberrant red cell ion channels, inflammation, thrombotic consequences, and the function of nitric oxide bioavailability are highlighted. We also discuss current developments in gene-based and pharmacologic therapy, such as gene editing techniques, hydroxyurea, antisickling medicines, and monoclonal antibodies. Translational attempts to create tailored therapies that aim to enhance the disease prognosis and quality of life for patients globally have been spurred by a thorough understanding of SCD at the molecular level.

Keywords

Sickle Cell, Disease, Molecular Mechanisms

1. Introduction

Sickle cell disease (SCD) is a hereditary blood ailment that is among the most prevalent monogenic conditions worldwide. A single point mutation in the β-globin gene (HBB) causes valine to replace glutamic acid at the sixth position of the β-globin chain. This alteration results in haemoglobin S (HbS), an abnormal type of haemoglobin. Individuals who inherit one copy of the faulty gene, commonly referred to as the carrier status, typically exhibit sickle cell trait, whereas those who inherit two copies, one from each parent, develop sickle cell disease (SCD). Globally, an estimated 300,000 babies are born with sickle cell disease annually; by 2050, this figure is predicted to rise to over 400,000, mostly due to population growth in high-burden areas [1].

People of African descent are disproportionately affected by malaria, along with populations in the Mediterranean, Middle East, and Indian subcontinent, where the sickle gene has traditionally provided some protection against the disease. In Nigeria, the country with the highest frequency of sickle cell disease (SCD) in the world, an estimated 150,000 infants are born with the disorder each year, contributing significantly to the morbidity and mortality of children in that country [2]. If timely and sufficient interventions are not given, many of these children die before they turn five.

The pathophysiology of sickle cell disease depends critically on how HbS functions in hypoxic or low-oxygen settings. Compared to normal haemoglobin (HbA), haemoglobin S is more likely to polymerise when deoxygenated. Because of this polymerisation, red blood cells (RBCs) become stiff, elongated, sickle-shaped cells instead of their usual flexible, biconcave disc shape. The reduced longevity, improved endothelium adhesiveness, and decreased deformability of these sickled RBCs result in recurrent bouts of vaso-occlusion. They obstruct blood flow in the microvasculature, resulting in ischaemic injury, acute pain episodes (sickle cell crises), and progressive damage to the heart, brain, kidneys, lungs, spleen, and lungs.

In sickle cell disease (SCD), the persistent haemolysis of red blood cells triggers oxidative stress and inflammatory pathways, leading to anaemia and the release of free haemoglobin and other intracellular components into the plasma. This exacerbates vascular dysfunction and increases the risk of complications like infection, pulmonary hypertension, leg ulcers, priapism, and stroke.

Even though SCD is a major public health concern in many parts of the world, especially sub-Saharan Africa, it still receives little financing and attention from international health programs. Because of advancements in molecular biology, early detection through newborn screening, preventative treatments like penicillin and hydroxyurea, and haematopoietic stem cell transplantation, results in high-income countries have greatly improved. However, these life-saving medicines are not available to many patients in low- and middle-income locations.

2. Sickle Cell Disease's Molecular Genetics

2.1 Mutation of the β-globin Gene

A single point mutation in the sixth codon of the β-globin gene (HBB), located on chromosome 11p15.5, causes sickle cell disease (SCD). A mutation that particularly involves an adenine (A) to thymine (T) transversion in the DNA sequence causes valine to replace glutamic acid at the sixth amino acid position of the β-globin chain of haemoglobin. E6V or Glu6Val are the names given to this mutation [3].

This seemingly insignificant genetic alteration has a major effect on the structure and function of haemoglobin. In healthy (oxygenated) conditions, haemoglobin S (HbS) can operate quite normally. However, under deoxygenated or hypoxic conditions, a sticky hydrophobic patch is introduced on the surface of the HbS molecule when valine, a nonpolar, hydrophobic amino acid, is substituted for the negatively charged, hydrophilic glutamic acid.
This abnormal hydrophobic interaction promotes the non-covalent polymerisation of deoxy-HbS molecules. These polymers produce long, rigid, and insoluble fibres inside the red blood cell (RBC), distorting its normal biconcave disc shape into the characteristic crescent or sickle shape. The polymerised haemoglobin fibres limit the RBCs' ability to deform and flow through the microvasculature. The rigid, sickled cells are more prone to hemolyze, have a substantially shorter lifespan (about 10–20 days compared to 120 days for normal RBCs), and contribute to chronic anaemia. Additionally, their altered shape and surface characteristics enhance adhesion to the vascular endothelium, leading to vaso-occlusion events, inflammation, and ischaemic tissue damage [4].

One sickle gene and one normal β-globin gene are inherited by people with sickle cell trait (HbAS). This heterozygous type is usually asymptomatic and does not display the severe clinical features of sickle cell disease. Importantly, the presence of HbAS provides a specific evolutionary advantage in regions where malaria is endemic, particularly in Africa. It is believed that the protective mechanism, which involves enhanced phagocytic clearance of parasitised erythrocytes and reduced parasite reproduction within sickled cells, provides partial immunity against severe Plasmodium falciparum malaria.

Conversely, people who have the HbS mutation (also known as the HbSS genotype) have every clinical indication of sickle cell disease. These include chronic haemolytic anaemia, repeated severe vaso-occlusive crises, and a range of organ issues, such as acute chest syndrome, splenic infarction, stroke, renal impairment, and retinopathy. The severity of the condition can vary widely across individuals and can also be influenced by other genetic modifiers, such as co-inheritance of α-thalassemia or persistence of foetal haemoglobin (HbF), which may lessen symptoms by preventing HbS polymerisation.

Understanding this molecular defect and its pathophysiological effects has played a major role in the development of customised treatments that aim to reduce HbS polymerisation, raise HbF levels, or correct the genetic mutation itself using cutting-edge gene-editing technologies.

2.2 Genetic Variables Affecting SCD Severity

The clinical manifestation of sickle cell disease (SCD) varies widely across affected individuals, even though the condition is caused by a single gene mutation. Even though they have the same HbSS genotype, this variation ranges from mild symptoms to potentially lethal outcomes. This variance highlights the significance of epigenetic factors and genetic modifiers in influencing the course and intensity of the disease. Understanding these modifiers is essential for prognosis, patient classification, and customised therapy plans. The following are some of the genetic modifiers that have the finest descriptions:

2.2.1 Foetal Haemoglobin, or HbF

One of the most potent natural markers of sickle cell disease severity is foetal haemoglobin (HbF). Adult haemoglobin (HbA), which is composed of two alpha and two gamma globin chains (α2γ2), typically takes the place of HbF after birth. However, some people can maintain high HbF levels into adulthood, which has a protective effect in SCD. By preventing the polymerisation of deoxygenated HbS, HbF lessens red blood cell sickling and the subsequent vaso-occlusive and haemolytic processes.

The production of HbF is influenced by the following genetic loci:

The transcriptional repressor BCL11A, which is found on chromosome 2p16, inhibits the expression of the gamma-globin gene. Variations in this gene that reduce its repressive effect may result in an increase in HbF levels. The HBS1L-MYB intergenic region on chromosome 6q23: Here, SNPs affect HbF levels indirectly via controlling the erythropoiesis-related gene MYB. Higher HbF expression and a less severe sickness phenotype are associated with the XmnI polymorphism (−158 C>T) in the Gγ-globin gene promoter. Given that patients with elevated HbF levels frequently have fewer haemolysis episodes, pain crises, and delayed start of sequelae, HbF induction is a crucial target for SCD treatment (such as hydroxyurea therapy.

2.2.2 Thalassaemia Alpha

Another significant modifier is alpha-thalassemia coinheritance, a condition characterised by a reduction in the synthesis of alpha-globin chains. This leads to a decreased intracellular concentration of haemoglobin, including HbS,

in people with sickle cell disease. Reduced HbS content in red blood cells reduces the propensity for polymerisation and the ensuing sickling, improving red cell survival and reducing haemolysis.

However, there are times when alpha-thalassemia in SCD has a beneficial therapeutic effect. It lowers haemolytic anaemia and some of its side effects (such as gallstones and leg ulcers), but it can also make blood more viscous, which might make vaso-occlusive episodes worse. The intricate relationships between altering genes and clinical outcomes in sickle cell disease are highlighted by this duality [5].

2.2.3 APOL1 Variants

The pathophysiology of chronic kidney disease (CKD) in people of African descent, especially those with sickle cell disease (SCD), has been linked to variations in the APOL1 gene, including the G1 and G2 risk alleles. Apolipoprotein L1, which is expressed in podocytes and other renal cells and is implicated in innate immunity, is encoded by APOL1.

Proteinuria, focal segmental glomerulosclerosis (FSGS), and end-stage renal disease (ESRD) are among the kidney-related problems that SCD patients with APOL1 risk variations are considerably more likely to have, according to studies. These correlations emphasise the necessity of nephroprotective measures and early screening in genetically vulnerable people [6].

In addition to these primary genetic modifiers, environmental variables, treatment compliance, gene polymorphisms that impact coagulation and inflammation, co-inheritance of β-thalassemia (compound heterozygosity), and healthcare accessibility all have an impact on the diverse spectrum of clinical outcomes in SCD [7].

Clinicians can more accurately forecast the course of the disease, customise treatment regimens, and create focused therapies to reduce problems in SCD patients by comprehending and recognising these modifiers.

3. Polymerisation of Haemoglobin and Red Cell Sickling

3.1 Polymerisation Mechanism

The polymerisation of haemoglobin S is the main molecular event in sickle cell disease.

The pathogenesis of sickle cell disease (SCD) is driven by the polymerisation of deoxygenated haemoglobin S (HbS), the disease's hallmark molecular event. This polymerisation is initiated by a structural abnormality in the HbS molecule caused by a single amino acid substitution at the sixth position of the β-globin chain: valine instead of glutamic acid. This change results in a hydrophobic patch on the surface of the haemoglobin molecule, notably on the β6 valine, under deoxygenated (hypoxic) conditions, which encourages abnormal intermolecular interactions between HbS molecules [8].

When the oxygen tension drops, the hydrophobic β6 valine bonds with a complementary hydrophobic pocket on a neighbouring haemoglobin molecule, initiating non-covalent aggregation. The production of long, inflexible fibres from the nucleation of these aggregates into double-stranded helical polymers distorts the red blood cell's flexible, biconcave disc shape into the characteristic elongated, sickle-shaped structure.

3.1.1 Thermodynamic and Environmental Factors

Thermodynamics controls the concentration-dependent HbS polymerisation process. High intracellular HbS concentrations (>20 g/dL) significantly increase polymer synthesis. Furthermore, several physiological and environmental factors exacerbate polymerisation, including:

Low pH (acidosis): Accelerates polymerisation by promoting haemoglobin destabilisation and deoxygenation. Because a higher temperature increases the kinetic energy of molecules, it promotes aggregation.

Cellular dehydration: Increases the amount of haemoglobin inside cells, which encourages the formation of polymers.

Hypoxia is the most significant trigger for HbS polymerisation because deoxygenated HbS has a significantly higher propensity to form polymers.

3.1.2 Polymerisation Kinetics and Sickling Dynamics

Rather than occurring instantly, HbS polymerisation is a two-phase kinetic process:

Phase of nucleation (delay time): Depending on intracellular conditions, this initial step is defined by the rate-limiting and highly variable formation of nuclei or small molecular aggregates. During this lag or delay period, sickling can be reversed if oxygen tension is quickly restored.

Phase of elongation: When stable nuclei form, polymer chains rapidly lengthen into long fibres. This phase proceeds more faster than nucleation and results in irreversible red blood cell deformation if the delay time is short in comparison to the transit time via the microvasculature [9].

The length of the delay time has a significant impact on the polymerization's result. Red blood cells are more likely to reoxygenate before fibres fully form, preserving their deformability, when delay times are longer. Shorter delay times, however, lead to the rapid formation of fibres and the persistence of sickling even after the cells return to oxygen-rich environments, particularly in dehydrated or acidotic cells.

3.1.3 Clinical Repercussions

The biophysical process of HbS polymerisation has important therapeutic implications. Because sickled cells are sticky and physically brittle, they interact with leukocytes, platelets, and the endothelium, which can result in haemolysis. Repetitive cycles of deoxygenation and reoxygenation damage membranes over time, resulting in a subpopulation of irreversibly sickled cells (ISCs) that induce chronic anaemia and microvascular blockage.

Furthermore, understanding polymerisation dynamics has impacted the development of several medicinal strategies intended to: HbS polymer synthesis is inhibited by increasing HbF levels. reducing HbS levels with medicine or water. preventing the formation of fibres by using drugs such as voxelotor, which increases the affinity of HbS for oxygen and reduces polymerisation.

In addition to being the first molecular lesion in SCD, HbS polymerisation is a dynamic and modifiable process. Due to its control by genetic, environmental, and therapeutic factors, there are substantial opportunities to improve clinical outcomes and reduce the burden of disease.

3.2 Recurrent Sickness and Cellular Deterioration

3.2.1 Red blood Cell Membrane Damage and the Emergence of Irreversibly Sickled Cells (ISCs)

In sickle cell disease (SCD), the membrane and cytoskeleton gradually deteriorate due to the frequent cycles of deoxygenation and reoxygenation that red blood cells (RBCs) undergo while in circulation. Even though sickling may be initially reversible, chronic exposure to stress from recurring polymerisation processes causes a subset of RBCs to become permanently sickled cells (ISCs), a rigid, non-deformable population that is essential to the pathogenesis of the disease [10].

3.2.2 Membrane and Cytoskeletal Disruption

Each HbS polymerisation and depolymerisation cycle results in mechanical stress on the RBC membrane. This stress progressively weakens the membrane lipid bilayer and the underlying spectrin-actin cytoskeleton, which are essential for maintaining the elasticity and shape of red blood cells. Ankyrin, spectrin, and protein 4.1 are examples of structural proteins that are broken down by oxidative and proteolytic mechanisms in the sickle cell environment. These proteins bind the membrane to the cytoskeleton.

Furthermore, because haemoglobin autoxidation and recurrent haemolysis increase the production of reactive oxygen species (ROS), oxidative stress impacts membrane components and promotes lipid peroxidation. These changes result in the cell being less deformable, the membrane becoming more rigid, and the cell becoming more brittle.

3.2.3 Dehydration and Ion Unbalance

Damaged red blood cell membranes cause ion channels and transporters to become dysregulated, which leads to electrolyte imbalances. The activation of potassium-chloride (K^+/Cl^-) cotransporters, Gardos channels (Ca^{2+}-activated K^+ channels), and nonspecific cation leak routes causes potassium efflux, calcium inflow, and water loss, which leads to cellular dehydration. The increased intracellular HbS level in dehydrated sickle cells promotes further polymerisation and strengthens the sickling cycle.

Apart from sickling, these ion and volume changes result in the appearance of phosphatidylserine (PS) on the outer membrane leaflet, which is normally exclusively present on the inner membrane. PS externalisation acts as a signal for macrophages to remove sickled red blood cells and adds to their procoagulant and sticky properties.

3.2.4 Characteristics and Impacts of Irreversibly Sickled Cells (ISCs)

Cells become irrevocably sickled as a result of the cumulative damage to the membrane and cytoskeleton. Unlike reversibly sickled cells, ISCs retain their distorted, rigid morphology even after reoxygenation. These cells:

lose their capacity for deformation, which is necessary for passing through the small capillaries and splenic sinusoids. Theyare vulnerable to intravascular or reticuloendothelial system early haemolysis. Theycause vascular obstruction and irritation by unsuitably attaching themselves to the vascular endothelium. Likwise, possess a longer half-life in circulation and are more likely to result in vaso-occlusive crises and end-organ damage.

The following are directly impacted by ISCs in circulation: haemolytic anemia—because they are more damaged and have a shorter lifespan. Microvascular occlusion is accomplished by obstructing capillaries and promoting leukocyte and platelet adhesion.

Tissue ischaemia and infarction are responsible for a number of the painful and frequently lethal side effects of sickle cell disease (SCD), including stroke, acute chest syndrome, and avascular necrosis.

4. Ion Channel Dysfunction and Red Cell Dehydration

4.1 Dehydration Mechanisms

4.1.1 Red Cell Dehydration's Role in HbS Polymerisation

One important factor that leads to sickling in sickle cell disease (SCD) is the intracellular dehydration of red blood cells (RBCs). Dehydrated red blood cells have increased intracellular concentrations of haemoglobin S (HbS), which accelerates polymerisation even under less severe hypoxic conditions. This mechanism raises the likelihood and severity of sickling events, which significantly affects haemolysis, vaso-occlusion, and the disease's overall progression.

Sickle cell disease (SCD) causes abnormal ion fluxes and net RBC water loss due to dysregulation of several ion transport pathways. Among the most important of them are the Psickle route, the Gardos channel, and the K-Cl cotransporter (KCC); each plays a distinct role in regulating red cell volume and dehydration.

4.1.2 The Gardos Channel on KCa3.1

The Gardos channel, also known as KCa3.1, is a Ca2+-activated potassium channel found in RBC membranes. When intracellular calcium levels increase, this channel opens to allow potassium ions (K^+) to exit the cell. Because of osmotic balance, water and chloride ions (Cl^-) follow, resulting in net cell dehydration.

The Gardos channel is hyperactivated in sickle cell disease (SCD) due to frequent deoxygenation episodes that promote calcium influx into red blood cells (RBCs). This causes chronic loss of potassium and water, which reduces cell volume and increases HbS levels. Because the increased intracellular HbS promotes faster polymerisation upon deoxygenation, the cells are more likely to adopt the sickled morphology.

Studies have shown that inhibiting the Gardos channel (for instance, with clotrimazole or senicapoc) might reduce RBC dehydration and sickling, making it an interesting therapeutic target [11].

4.1.3 K-Cl Cotransporter, or KCC

The K-Cl cotransporter is another significant element that plays a role in red cell dehydration (KCC). Along with the electroneutral export of K+ and Cl+ ions from the RBC, it promotes passive water loss. In immature red blood cells and under certain stress responses, KCC is biologically active; however, in sickle cell disease (SCD), its activity is unusually high.

Important elements that encourage KCC activity include the following:

acidic pH (acidosis) within cells, cell enlargement, Low oxygen tension, often known as hypoxia

These circulatory abnormalities are common in sickle cell disease patients, particularly during vaso-occlusive episodes. RBC volume further decreases due to increased KCC activity, which increases intracellular HbS concentration and promotes HbS polymerisation and sickling [12].

KCC activity is significantly higher in reticulocytes (immature RBCs), which are commonly elevated in sickle cell disease (SCD) as a result of enhanced haemolysis and compensatory erythropoiesis.

4.1.4 The Psickle Trail

Deoxygenation triggers the Psickle pathway, a poorly understood cation conductance mechanism unique to sickle red blood cells. This mechanism, whose chemical identity is still being investigated, is activated by low oxygen levels and permits calcium ions (Ca2+) to enter the cell.

This increased intracellular Ca2+ level indirectly activates the Gardos channel, initiating the chain reaction of K^+ loss and water efflux that leads to dehydration. The possible involvement of the Psickle pathway in membrane depolarisation and altered phospholipid distribution may further enhance red cell stiffness and adhesiveness [13].

Because the Psickle pathway is sensitive to deoxygenation, especially in post-capillary venules where oxygen tension is typically low, it functions as an early amplifier of RBC dehydration during transit through the microvasculature.

4.1.5 Clinical Repercussions

These pathways' involvement in RBC dehydration and increased HbS polymerisation makes them attractive therapeutic targets. Several pharmacologic compounds under investigation aim to:

Block or alter the Gardos channel (e.g., senicapoc) to preserve cell hydration.

Put an end to KCC operations or the upstream regulators that manage them.

Psick or adjust the calcium balance

4.2 Targeting Therapy

Targeting ion transport pathways with pharmacologic methods has garnered a lot of attention since RBC dehydration is crucial in accelerating HbS polymerisation and sickling. Since it directly contributes to the water and potassium outflow

from sickle red blood cells, the Gardos channel (KCa3.1) has emerged as a particularly desirable target among them. Red cell hydration may be preserved, intracellular HbS concentration may be reduced, and the sickling-causing polymerisation cascade may be inhibited by inhibiting this channel.

Senicapoc: A Particular Gardos Channel Inhibitor
Senicapoc (ICA-17043) specifically and substantially inhibits the Gardos channel. By preventing calcium-activated potassium export, senicapoc helps maintain intracellular potassium and water levels while preventing red cell shrinkage and dehydration. This procedure was expected to improve the biophysical properties of sickle RBCs and reduce hemolysis-related challenges.

In phase II clinical trials, senicapoc demonstrated encouraging haematologic improvements in sickle cell disease patients:

Increased haemoglobin levels

Reduced reticulocyte counts

Decreased levels of lactate dehydrogenase (LDH) and bilirubin

Reduced haemolysis indicators overall

These changes demonstrated reduced red cell death and increased red cell survival, suggesting that senicapoc effectively reduced the haemolytic component of SCD pathogenesis [14].

Limitations and Phase III Findings
Despite these positive results, a second phase III trial evaluating the impact of senicapoc on clinical outcomes, specifically the incidence of painful vaso-occlusive crises (VOCs), yielded disappointing results. Even while the drug continued to improve haematological markers, there was no statistically significant reduction in pain episodes or hospitalisations when compared to a placebo.

This finding brought to light an important realisation: whereas haemolysis and RBC dehydration exacerbate the situation, they may not be the only factors contributing to vaso-occlusive crises. Additionally, inflammation, leukocyte adhesion, platelet activation, and endothelial dysfunction cause and sustain these excruciating episodes.

As a result, the SCD development project was abandoned despite the fact that senicapoc improved laboratory measures.

The clinical course of senicapoc emphasises the complex and multidimensional nature of SCD aetiology. It also suggests that successful pharmacologic strategies may need to simultaneously target multiple pathways, including:

mixing anti-dehydration drugs with adhesion-blocking substances, HbF inducers, or anti-inflammatory drugs.

identifying the patient groupings that would benefit more from Gardos inhibition, such as those with mainly haemolytic characteristics.

Additionally, other compounds that affect RBC hydration and ion flow, like intracellular calcium modulators, KCC inhibitors, or targeted antioxidants, are still being studied as supplements or alternatives to current treatments like voxelotor and hydroxyurea.

5. Haemolysis and Nitric Oxide Scavenging

5.1 Mechanisms of Haemolysis

In SCD, haemolysis can occur both intravascularly and extravascularly. Intravascular haemolysis poses a particular risk since it releases free haemoglobin, heme, and iron into the blood. Free haemoglobin binds nitric oxide (NO) strongly, forming methaemoglobin and nitrate, which lowers NO's bioavailability [15].

5.2 The NO Scavenging and Vascular Dysfunction

NO is a vital vasodilator and anti-adhesive substance. Its loss aggravates pulmonary hypertension, endothelial activation, platelet aggregation, and vasoconstriction.
Additionally, heme is a pro-oxidant that triggers TLR4 signalling in immune cells and endothelium, which leads to additional inflammation [11].

5.3 Heme Oxygenase-1, or HO-1

HO-1 breaks down heme to create biliverdin, carbon monoxide, and free iron. It has anti-inflammatory, antioxidant, and cytoprotective qualities. As a protection against heme toxicity, HO-1 expression is elevated in SCD [15].

6. Vaso-occlusion and Endothelial Dysfunction

6.1 Vascular Adhesion

Vaso-occlusion, a feature of sickled cell disease, is brought on by the sticky interaction of sickled red blood cells, leukocytes, platelets, and endothelial cells. Inflammatory conditions increase VCAM-1, ICAM-1, P-selectin, and E-selectin on the endothelium, which promotes cellular adhesion [8].

Adhesion is further enhanced by increased expression of integrins and CD36 on RBCs and Mac-1 on neutrophils.

6.2 Leukocyte and Platelet Activation

Activated neutrophils and monocytes release proinflammatory cytokines, including TNF-α and IL-1β, which promote endothelial activation. Neutrophils create neutrophil extracellular traps (NETs), which enhance microvascular obstruction [16].

The chronic activation of platelets in sickle cell disease (SCD) promotes leukocyte migration and thrombin synthesis.

6.3 Dysfunction of the Endothelium and Reduced NO

Low NO levels prevent vasodilation and promote a proadhesive endothelium phenotype. Prolonged oxidative stress damages endothelial tight junctions, increases vascular permeability, and promotes inflammation [9].

7. Oxidative Stress and Dysfunctional Mitosis

Sickle cell disease is brought on by prolonged oxidative stress. Among the causes of ROS in SCD include heme-driven Fenton reactions, xanthine oxidase activity, NADPH oxidase activation, and HbS auto-oxidation. ROS damage membrane lipids, oxidise proteins, and degrade DNA. Damaged red blood cells emit microparticles that worsen inflammation and clotting. Moreover, oxidative stress is increased by mitochondrial dysfunction in reticulocytes [17].

8. Activation of Coagulation and Thrombosis

Indicators of the hypercoagulable state associated with sickle cell disease (SCD) include elevated tissue factor on monocytes and endothelial cells, increased D-dimer, prothrombin fragment 1.2, and thrombin-antithrombin complexes; platelet hyperactivity; and the formation of microparticles from hemolyzed red blood cells and activated platelets [18].

These factors increase the risk of thrombotic side effects, such as stroke, deep vein thrombosis, and pulmonary embolism. Children with sickle cell disease (SCD) are 200 times more likely to have an ischaemic stroke than their healthy counterparts [19].

9. Multiple Organ Damage and Clinical Symptoms

Over time, chronic inflammation, vaso-occlusion, and haemolysis result in cumulative organ damage:

• Central Nervous System: quiet infarcts, overt strokes, and cognitive deterioration.

• The pulmonary system, which encompasses acute chest syndrome, restrictive lung disease, and pulmonary hypertension.

• Renal System: renal papillary necrosis, haematuria, hyposthenuria, and chronic kidney disease.

• Hepatosplenic involvement includes splenic infarction, liver failure, and functional asplenia.

• Osteomyelitis and avascular necrosis, particularly of the femoral head, in the musculoskeletal system.

• Ophthalmologic: Retinopathy-induced vision loss [20].

10. Novel Therapies: Targeting Molecular Pathways

Several cutting-edge treatments have been developed as a result of a better understanding of the biology of SCD:

Clinical Benefits of Medication Mechanism

Hydroxyurea improves survival and reduces disasters by lowering the WBC count and increasing HbF [21].

Oxidative stress is reduced by L-glutamine, which also lowers hospitalisation and pain episodes [8].

The Voxelotor stabilises oxygenated HbS and stops polymerisation. increases haemoglobin and decreases haemolysis [22].

Vaso-occlusive crises are less likely to develop when crizanlizumab inhibits P-selectin and decreases cell adhesion [23].

Recent research suggests a potential treatment by correcting the HBB mutation or reactivating HbF through gene therapy (CRISPR/Cas9, for instance) [24].

11. Conclusion

Sickle cell disease is produced by a complex interplay of systemic, cellular, and molecular mechanisms, while it is primarily caused by a single point mutation. Its pathophysiology depends on the polymerisation of HbS and the resulting RBC sickling, which results in end-organ damage, inflammation, haemolysis, and vaso-occlusion. Along with unravelling these intricate processes, molecular biology breakthroughs have spurred the development of innovative therapies, from gene-editing methods that promise a functional cure to pharmaceutical drugs that target adhesion and oxidative stress. It will need continued translational research and equitable access to new medications to turn sickle cell disease (SCD) from a deadly condition into a chronic one that can be controlled.

References

[1] Hebbel RP, Vercellotti GM. Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level. Blood Reviews. 2023;57:100973.
[2] Ferrone FA, Eaton WA. Sticking together: Polymerization of sickle hemoglobin drives the multiscale pathophysiology of sickle cell disease. Biophysics Reviews. 2025;7(2):021302. doi:10.1063/5.0154210
[3] Abraham DJ, Mozzarelli A, Safo MK. X-ray crystallography and sickle cell disease drug discovery—a tribute to Donald Abraham. Front Mol Biosci. 2023;10:1136970.
[4] Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2023;18:113–140.
[5] Wang Y, Gordeuk VR, Saraf SL, et al. Genome-wide association study identifies novel fetal hemoglobin regulators in sickle cell disease. Nat Commun. 2025;16:2143.
[6] Ghatpande A, Ghatpande S, Tisdale JF. Genetic modifiers and therapeutic targets in sickle cell disease. Annu Rev Genomics Hum Genet. 2023;24:345–368.
[7] Dasgupta T, Yang C, Aggarwal S, et al. Molecular mechanisms of hepatic dysfunction in sickle cell disease: insights from the Townes mouse model. Am J Physiol Gastrointest Liver Physiol. 2023;324(4):G311–G320.
[8] Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A. 2024;121(7):12345–12352.
[9] Asare E, Pacelli M, Tassinari L, et al. Metabolic reprogramming in sickle cell disease: pathophysiology and drug discovery opportunities. Int J Mol Sci. 2022;23(13):7448. doi:10.3390/ijms23137448
[10] Morris CR, Vichinsky EP. Innovations in oxidative stress management in sickle cell disease: the NRF2 pathway and beyond. Antioxidants (Basel). 2024;13(2):302.
[11] Hardouin G, Magrin E, Corsia A, Cavazzana M, Miccio A, Semeraro M. Sickle Cell Disease: From Genetics to Curative Approaches. Annu Rev Genomics Hum Genet. 2023;24:255–275.
[12] Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Telomere Dynamics in Sickle Cell Anemia: Unraveling Molecular Aging and Disease Progression. J Blood Med. 2024;15:313–323.
[13] Starlard-Davenport A, Palani CD, Zhu X, Pace BS. Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation—A Short Review. Int J Mol Sci. 2025;26(9):4192.
[14] Liebendorfer A. Molecular methods to analyze sickle cells provide deeper insight into therapeutics. Scilight (AIP Publishing). 2025;121111(2025).
[15] Ababio GK. Emerging Trends in Sickle Cell Disease and CRISPR/Caspases. In: Zakaria M, editor. Curr Practices in Sickle Cell Disease. IntechOpen; 2024 Apr: chap Front matter. Discusses CRISPR-based editing of the β-globin mutation, oxidative stress, and caspase-mediated pathways IntechOpen.
[16] Dorneles J, Mayer AM, Chies JAB. Sickle Cell Anemia and Inflammation: A Review of Stones and Landmarks Paving the Road in the Last 25 Years. Hematol Rep. 2025;17(1):2.
[17] Telen MJ, Malik P, Vercellotti GM. Sickle cell dehydration: pathophysiology and therapeutic applications. Blood Rev. 2018;32(4):176–183.
[18] Lew VL, Bookchin RM. Ion transport pathology in the mechanism of sickle cell dehydration. Am J Hematol. 2005;80(1):59–61.
[19] Franco RS, et al. Pathophysiology of Sickle Cell Disease and New Drugs for the Treatment. Am J Pathol. 2011;178(5):2044–2055.
[20] Vona, R.; Sposi, N.M.; Mattia, L.; Gambardella, L.; Straface, E.; Pietraforte, D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. Antioxidants 2021, 10, 296.
[21] Ala C. A review on disease modifying pharmacologic therapies for sickle cell disease. Ann Hematol. 2025;104(7):881–893.
[22] Wonkam A. The future of sickle cell disease therapeutics rests in genomics. Dis Model Mech. 2023;16(2):dmm049765.
[23] Blatt P, Ferrone FA, Eaton WA. Sticking together: polymerization of sickle hemoglobin drives the multiscale pathophysiology of sickle cell disease. Biophys Rev. 2025;7(2):021302.
[24] Chang AK, Ginter-Summarell CC, Birdie PT, Sheehan VA, Connes P. Genetic modifiers of severity in sickle cell disease. Clin Hemorheol Microcirc. 2018;70(1-2):29–40.